The Theranos saga has captivated onlookers in Silicon Valley, the medical technology industry and the corporate world in general. With plenty of take-aways for everyone from investors to lab technicians, it’s not hard to see Elizabeth Holmes being mentioned in cautionary tales for years to come.

As Holmes’ trial for wire fraud gets under way this week, the exact shape of those lessons remains to be determined.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]